Here are the 424B prospectus supplements from Theriva Biologics, Inc. (TOVX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TOVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TOVX filings page.
Theriva Biologics, Inc. is registering 16,184,560 shares of common stock for resale by existing investors, covering shares issuable upon exercise of “New Warrants” issued in an October 2025 warrant inducement transaction. Those investors had previously held warrants to buy 8,092,280 shares, which they agreed to exercise for cash at a reduced price of $0.54 per share. In return, Theriva issued New Warrants for 16,184,560 additional shares, also at $0.54 per share.
Theriva has already received approximately $4.4 million in gross proceeds from the exercised prior warrants, before fees. The company will not receive any proceeds from resale of the registered shares, but would receive cash only if holders exercise the New Warrants. Shares outstanding were 33,739,643 as of November 3, 2025, and would be 49,924,203 assuming full exercise of the New Warrants. The stock last closed at $0.2189 per share on the NYSE American under the symbol “TOVX.”